1994
DOI: 10.1097/00002030-199402000-00004
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
15
0

Year Published

1995
1995
2005
2005

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 20 publications
(15 citation statements)
references
References 0 publications
0
15
0
Order By: Relevance
“…The neutralization potency of the corresponding whole antibody may be considerably greater (up to 100-fold [47]); this is currently being investigated. In a previous study by D'Souza et al (19), it was suggested that 4E10 was able to neutralize certain T-cell-line-adapted subtype B isolates of HIV-1. More recently, Xu et al (79) showed that 4E10 was able to potently neutralize the subtype C isolate BW11.…”
Section: Discussionmentioning
confidence: 96%
“…The neutralization potency of the corresponding whole antibody may be considerably greater (up to 100-fold [47]); this is currently being investigated. In a previous study by D'Souza et al (19), it was suggested that 4E10 was able to neutralize certain T-cell-line-adapted subtype B isolates of HIV-1. More recently, Xu et al (79) showed that 4E10 was able to potently neutralize the subtype C isolate BW11.…”
Section: Discussionmentioning
confidence: 96%
“…[9][10][11] It is essential to develop the most relevant neutralization assay taking into account these different points. Two protocols are currently used: (1) an antibody end-point dilution assay, which is based on the incubation of a fixed inoculum of virus with serial dilutions of antibody, and (2) an infectivity reduction assay, which is based on the incubation of serial dilutions of virus with a single amount of antibody.12 This article describes an assay de-veloped for studying the neutralization of primary isolates obtained at an early time of infection and cultured only on primary cells (human PBMCs) that combines these two approaches: serial dilutions of viruses neutralized by serial dilutions of antibody.…”
Section: Introductionmentioning
confidence: 99%
“…One of the consequences of this quaternary arrangement is that a number of conserved epitopes that are well exposed on purified, monomeric gp120 and gp41 are buried or partially buried in the trimeric gp120-gp120, gp41-gp41, or gp120-gp41 interfaces within the native spike (29,62,67,69,86). The relative inaccessibility of conserved epitopes in the trimeric spike likely explains the paucity of neutralizing monoclonal antibodies against HIV-1 (8) as well as the low titers of isolate crossneutralizing antibodies typically found in the serum of animals or humans immunized with soluble envelope protein (15,20,21,23,26,45,72,81,85) or even during natural infection with HIV-1 (38,48).…”
mentioning
confidence: 99%